Glucosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients

A. Ceriello, A. Quatraro, M. Ettorre, E. Marchi, M. Barbanti, D. Giugliano

Research output: Contribution to journalArticlepeer-review


High fibrinogen plasma levels are associated with an increased risk of cardiovascular disease. There is evidence that both increased fibrinogen plasma levels and thrombin formation may be present in subjects with diabetes mellitus. This study shows that in hyperfibrinogenemic (fibrinogen>300 mg/dl) diabetic subjects increased fibrinogen plasma level is associated with increased thrombin formation evaluated by fibrinopeptide A plasma levels. The administration of four different glucosaminoglycans, vs placebo, reduces both fibrinopeptide A and fibrinogen levels. These data suggest that, in diabetes, hyperfibrinogenemia may be associated with increased thrombin formation, and that elevated fibrinogen and increased thrombin formation may be reduced by glucosaminoglycans administration.

Original languageEnglish
Pages (from-to)203-206
Number of pages4
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Issue number4
Publication statusPublished - 1993


  • diabetes
  • fibrinogen
  • Glucosaminoglycans

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Internal Medicine
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Glucosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients'. Together they form a unique fingerprint.

Cite this